Prevalence of HEV RNA in Croatian blood donors.

Blood donors Hepatitis E virus (HEV) NAT testing Prevalence Transfusion-transmission

Journal

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine
ISSN: 1953-8022
Titre abrégé: Transfus Clin Biol
Pays: France
ID NLM: 9423846

Informations de publication

Date de publication:
May 2023
Historique:
received: 30 11 2022
revised: 17 01 2023
accepted: 19 01 2023
medline: 28 4 2023
pubmed: 29 1 2023
entrez: 28 1 2023
Statut: ppublish

Résumé

HEV infection is asymptomatic for immunocompetent blood donors (BD). Transfused HEV-infected blood products may cause potentially hazardous HEV infection in immunocompromised patients. Evaluation of the need for routine BD HEV RNA screening primarily demands the establishment of HEV infection prevalence in Croatian BD. We tested BD samples in ID-NAT with the Procleix UltrioPlex E screening test for simultaneous detection of HBV DNA, HCV RNA, HIV-1,2 RNA, and HEV RNA (Grifols, Spain). HEV infection was confirmed with HEV RNA quantitative test (Altona Diagnostics, Germany) and HEV IgM and HEV IgG antibody test (DIA.PRO Diagnostic Bioprobes, Italy). We analysed the HEV RNA sequence and performed a phylogenetic analysis. We recorded BD's anamnestic data and dietary habits. BDs gave follow-up samples after two months and did not donate blood for six months. Between December 2021 and March 2022, we tested 8,631 donations and found four HEV RNA-positive donations, which equals to one in 2,158 donations (0.046 %, 95 % confidence interval, 0.018 %-0.119 %). Confirmatory HEV RNA testing gave results from negative to 4.73E + 3 IU/ml HEV RNA. Three donations were in the serological window period. We have genotyped HEV RNA of two infected BD as genotype HEV-3c. Blood donors didn't report any health problems and their diet included pork. Testing on follow-up samples presented seroconversion and no HEV RNA could be detected. The incidence of HEV RNA infection in BD in Croatia corresponds with other European data. The decision on implementation of HEV NAT screening in Croatia needs an expert team evaluation of the possible risk of TT-HEV infection.

Identifiants

pubmed: 36708916
pii: S1246-7820(23)00024-1
doi: 10.1016/j.tracli.2023.01.005
pii:
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

244-248

Informations de copyright

Copyright © 2023 Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

I Gorski (I)

Jasika, Dolenica 55, 10250 Zagreb, Croatia. Electronic address: ivana.tomicic@jasika.hr.

I Babić (I)

Croatian Institute of Transfusion Medicine (CITM), Petrova 3, 10000 Zagreb, Croatia. Electronic address: ivana.babic@hztm.hr.

J Bingulac-Popović (J)

Croatian Institute of Transfusion Medicine (CITM), Petrova 3, 10000 Zagreb, Croatia. Electronic address: jasna.bingulac-popovic@hztm.hr.

P Topić-Šestan (P)

Croatian Institute of Transfusion Medicine (CITM), Petrova 3, 10000 Zagreb, Croatia. Electronic address: patricija.topic-sestan@hztm.hr.

S Jagnjić (S)

Croatian Institute of Transfusion Medicine (CITM), Petrova 3, 10000 Zagreb, Croatia. Electronic address: sandra.jagnjic@hztm.hr.

L Jemeršić (L)

Croatian Veterinary Institute, Savska 143, 10000 Zagreb, Croatia. Electronic address: jemersic@veinst.hr.

J Prpić (J)

Croatian Veterinary Institute, Savska 143, 10000 Zagreb, Croatia. Electronic address: balatinec@veinst.hr.

I Jukić (I)

Croatian Institute of Transfusion Medicine (CITM), Petrova 3, 10000 Zagreb, Croatia; Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Trg Svetog Trojstva 3, 31000 Osijek, Croatia. Electronic address: irena.jukic@hztm.hr.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH